- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04921748
Neurorehabilitation of Sequence Effect in Parkinson's Disease
Destination Sequence Effect Modifications After a 4-week Rehabilitation Program in Parkinson's Diseases Patients
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Gait impairment and freezing of gait (FOG) represent common and disabling symptoms of Parkinson's disease (PD). The antiparkinsonian therapy positively modulates a subset of gait parameters, such as speed of gait and stride length, while its impact on FOG is limited. Growing evidence supports the efficacy of neurorehabilitation in the treatment of PD across all phases of the disease. In the last years, the advent of reliable wearable devices has prompted the widespread study of several parameters of the parkinsonian gait in both clinical and research settings.
The sequence effect (SE), defined as a reduction in amplitude of repetitive movements, is a common clinical feature of several tasks of patients affected by PD, being identifiable in early as well as advanced stages of the disease. During walking, SE manifests as a step-by-step reduction in step length when approaching a turn or gait destination (destination sequence effect - dSE). SE is specifically pronounced in PD patients affected by FOG, and it arises immediately before a FOG episode induced by a turning or a dual-task.
SE may be acutely modulated by several rehabilitative strategies such as split-belt treadmill and reinforcement of visual cues, but not by repetitive transcranial magnetic stimulation (rTMS), antiparkinsonian drugs administration, and attention strategies did not influence the SE, the evidence on the role of neurorehabilitation on gait SE improvement and retention is extremely scarce.
The investigators plan to enroll 43 subjects according to sample size calculation. Patients will be divided into two groups: patients with freezing of gait (FOG) and without FOG. The subjects will be divided into two groups: 1) patients with freezing of gait (PD+FOG), or 2) patients without freezing of gait (PD-FOG). FOG phenotype is defined as: a score between 1 and 4 at either item "2.13 Freezing" or item "3.11 Freezing of gait" of the Unified Parkinson Disease Rating Scale (UPDRS).
All patients will be treated with a standardized 4-week rehabilitation in-hospital program. At hospital admission (T0), patients who fulfill inclusion/exclusion criteria will be tested with instrumental gait analysis and administration of a set of the following clinical scales: rating of PD related motor disability with the Unified Parkinson's Disease Rating Scale - part III (UPDRS-III); rating of functional independence as measured through the Functional Independence Measure (FIM); and rating of dependence in activity of daily living according to Barthel Index.
After that, patients will be treated with 90-minute daily rehabilitative sessions, 6 days a week (Monday through Saturday) for four weeks (passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing). The rehabilitation program will be the same in PD+FOG and PD-FOG groups. At the end of the rehabilitation program (T1), the patients will complete the study procedure with a second instrumental gait analysis evaluation and the administration of the same set of clinical scales. No modifications of the drug regimen were allowed during the study.
The gait analysis will be performed with wearable, wireless, inertial system, secured to the back of the patients between L5 and S1 vertebrae. All subjects will be recorded in the morning (between 9:00 a.m. and 11:00 a.m.) and in the ON condition. The investigators plan to record a walk, at a comfortable pace, of 20 meters. The subjects will stop independently at the end of the 20-meter pathway, clearly marked by a straight line on the ground. Gait assessments with episodes of freezing of gait or pauses will be discrded. For each subject, three optimal performed gait assessments will be recorded. Regarding gait parameters the investigators will record: speed (m/s), cadence (steps/minute), stride length (meter), step length (meter), stride duration (second), single support, double support, swing duration, stance duration (percentage stride distribution). The destination Sequence Effect (dSE) will be computed as a regression slope (β) of step length according to a previously described and validated methodology where step length is plotted against step number. Briefly, the length of the last six steps ahead of the final stride are plotted against the step number, and the linear regression slope (β) will represent a measure of dSE. In addition, the intercept (I) of the regression curve will be used as an indirect measure of gait hypokinesia. For each group, the relationship between gait hypokinesia and sequence effect is expressed by the function of the linear regression as follow: y = β (x) + I.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Pavia, Itália, 27100
- IRCCS Mondino Foundation
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Idiopathic Parkinson's disease
- Hoehn and Yahr stage between I and IV
- Mini-Mental State Examination score above 24.
Exclusion Criteria:
- Major psychiatric or other neurological conditions,
- Rheumatological diseases
- Ophthalmic diseases
- Orthopedic diseases
- Ongoing or previous treatment with neuroleptic drugs
- Patients with deep brain stimulation
- Any change in dose or regimen of the anti-parkinsonian therapy in the last month before enrolment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
---|---|
PD+FOG group
Patients affected by Parkinson's Disease with freezing of gait (PD+FOG group)
|
All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks.
The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
Outros nomes:
|
PD-FOG group
Patients affected by Parkinson's Disease without freezing of gait (PD+FOG group)
|
All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks.
The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Destination sequence effect (dSE) modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of destination sequence effect in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Between-group comparison of dSE
Prazo: Baseline (T0)
|
Comparison of destination Sequence Effect in PD patients with FOG vs. PD patients without FOG
|
Baseline (T0)
|
Gait hypokinesia modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of intercept "I" in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Speed modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of speed (m/s) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Cadence modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of cadence (steps/min) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Stride duration modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of stride duration (s) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Stride lenght modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of stride length (m) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Stance modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of stance phase (%) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Swing modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of Swing phase (%) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Double support modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of double support (%) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Single support modifications
Prazo: Change from baseline (T0) to four weeks (T1)
|
Using an inertial gait analysis we will explore the modifications of single support (%) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Motor disability improvement
Prazo: Change from baseline (T0) to four weeks (T1)
|
We will explore the changes in motor disability as measured by Unified Parkinson Disease Rating Scale - part III (UPDRS-III) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Functional Independence improvement
Prazo: Change from baseline (T0) to four weeks (T1)
|
We will explore the changes in functional independence as measured by Functional Independence Measure (FIM) in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Dependence in activity of daily living improvement
Prazo: Change from baseline (T0) to four weeks (T1)
|
We will explore the changes in dependence in activity of daily living as measured by barthel Index in PD patients with and without freezing of gait treated with a 4-week in-hospital rehabilitation program
|
Change from baseline (T0) to four weeks (T1)
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Roberto De Icco, MD, IRCCS Mondino Foundation, Pavia
Publicações e links úteis
Publicações Gerais
- Kang SY, Wasaka T, Shamim EA, Auh S, Ueki Y, Lopez GJ, Kida T, Jin SH, Dang N, Hallett M. Characteristics of the sequence effect in Parkinson's disease. Mov Disord. 2010 Oct 15;25(13):2148-55. doi: 10.1002/mds.23251.
- Cao SS, Yuan XZ, Wang SH, Taximaimaiti R, Wang XP. Transverse Strips Instead of Wearable Laser Lights Alleviate the Sequence Effect Toward a Destination in Parkinson's Disease Patients With Freezing of Gait. Front Neurol. 2020 Aug 12;11:838. doi: 10.3389/fneur.2020.00838. eCollection 2020.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Neurorehab in PD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença de Parkinson
-
ProgenaBiomeRecrutamentoDoença de Parkinson | Doença de Parkinson com Demência | Parkinson-Síndrome Demencial | Doença de Parkinson 2 | Doença de Parkinson 3 | Doença de Parkinson 4Estados Unidos
-
National Yang Ming UniversityDesconhecidoDoença de Parkinson de Início Precoce | Doença de Parkinson em estágio inicial
-
National Heart, Lung, and Blood Institute (NHLBI)ConcluídoDoença de Parkinson 6, de início precoce | Doença de Parkinson (Autossômica Recessiva, Início Precoce) 7, Humana | Doença de Parkinson Autossômica Recessiva de Início Precoce | Doença de Parkinson, Autossômica Recessiva de Início Precoce, Digênica, Pink1/Dj1Estados Unidos
-
Ahram Canadian UniversityAin Shams UniversityRecrutamentoDoença de Parkinson | Parkinson | Doença de Parkinson e ParkinsonismoEgito
-
Samuel Vilchez, PhDNational Autonomous University of Nicaragua; Wake Forest University; GID BIO,... e outros colaboradoresConcluídoDoença de Parkinson e Parkinsonismo | Doença de Parkinson IdiopáticaNicarágua
-
King's College LondonGlaxoSmithKlineConcluídoDoença de Parkinson | Doença de Parkinson Idiopática | Doença de Parkinson, PARK8Reino Unido
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationDesconhecidoControles Saudáveis | Doença de Parkinson com mutação LRRK2 | Doença de Parkinson sem mutação LRRK2França
-
Professor Lu Neurological ClinicDesconhecidoDoença de Parkinson de Início PrecoceTaiwan
-
PureIMS B.V.Cooperative Clinical Drug Research and Development AG (CCDRD AG)ConcluídoDoença de Parkinson | Parkinson | Doença de Parkinson e ParkinsonismoBulgária
-
Cedars-Sinai Medical CenterRecrutamentoDistúrbio Comportamental do Sono REM | Doença de Parkinson pré-motora | Doença de Parkinson sintomáticaEstados Unidos